tiprankstipranks
Advertisement
Advertisement

MRNA Stock Latest News

Moderna price target raised to $39 from $33 at Morgan Stanley
The FlyModerna price target raised to $39 from $33 at Morgan Stanley
14h ago
MRNA
Moderna Strengthens Board with New Financial Director
PremiumCompany Announcements
Moderna Strengthens Board with New Financial Director
15h ago
8K
MRNA
Moderna appoints Michael McDonnell to Board of Directors
PremiumThe Fly
Moderna appoints Michael McDonnell to Board of Directors
15h ago
MRNA
Moderna price target raised to $38 from $34 at BofA
PremiumThe Fly
Moderna price target raised to $38 from $34 at BofA
2d ago
MRNA
Moderna price target raised to $45 from $38 at RBC Capital
PremiumThe Fly
Moderna price target raised to $45 from $38 at RBC Capital
2d ago
MRNA
Moderna’s Pipeline Hype Sends Shares Soaring Again
PremiumWeekend UpdatesModerna’s Pipeline Hype Sends Shares Soaring Again
5d ago
MRNA
Early notable gainers among liquid option names on July 2nd
Premium
The Fly
Early notable gainers among liquid option names on July 2nd
7d ago
HCA
COIN
Moderna’s Surprise Surge: Is the mRNA Giant Back?
Premium
Weekend Updates
Moderna’s Surprise Surge: Is the mRNA Giant Back?
12d ago
MRNA
Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026
PremiumMarket News
Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026
12d ago
MRNA
Moderna rises 14.2%
PremiumThe Fly
Moderna rises 14.2%
12d ago
MRNA
Moderna rises 8.7%
PremiumThe Fly
Moderna rises 8.7%
12d ago
MRNA
Early notable gainers among liquid option names on June 26th
PremiumThe Fly
Early notable gainers among liquid option names on June 26th
13d ago
FDS
LLY
Moderna price target raised to $77 from $69 at Piper Sandler
PremiumThe FlyModerna price target raised to $77 from $69 at Piper Sandler
13d ago
MRNA
Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks
Premium
Ratings
Moderna Maintained at Hold as Analyst Weighs Leading mRNA Platform Against Early-Stage Pipeline Risks
13d ago
MRNA
Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks
Premium
Ratings
Hold Rating Reiterated on Moderna as Analyst Keeps $49 Price Target Amid Long-Term Pipeline Potential and Near-Term Execution Risks
13d ago
MRNA
Hold Rating Reaffirmed on Moderna as Analyst Highlights High-Risk/High-Reward Pipeline and Keeps Price Target Unchanged at $41
PremiumRatings
Hold Rating Reaffirmed on Moderna as Analyst Highlights High-Risk/High-Reward Pipeline and Keeps Price Target Unchanged at $41
13d ago
MRNA
Analyst Maintains Sell on Moderna as Shares Trade Above Unchanged $34 Price Target Despite Scientific Momentum
PremiumRatings
Analyst Maintains Sell on Moderna as Shares Trade Above Unchanged $34 Price Target Despite Scientific Momentum
13d ago
MRNA
Moderna Science Day highlights potential of mRNA platform
PremiumThe Fly
Moderna Science Day highlights potential of mRNA platform
14d ago
MRNA
Early notable gainers among liquid option names on June 23rd
PremiumThe Fly
Early notable gainers among liquid option names on June 23rd
15d ago
CDW
IBM
Moderna Stock Jumps as Pipeline Hype Outruns Wall Street
PremiumWeekend UpdatesModerna Stock Jumps as Pipeline Hype Outruns Wall Street
19d ago
MRNA
Moderna announces FDA advisory committee votes in favor of mRNA-1010
Premium
The Fly
Moderna announces FDA advisory committee votes in favor of mRNA-1010
20d ago
MRNA
Moderna up 4% after FDA advisers back flu vaccine approval
Premium
The Fly
Moderna up 4% after FDA advisers back flu vaccine approval
20d ago
MRNA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >